羟考酮缓释片单用或联合氟伏沙明治疗中重度癌痛合并抑郁的效果观察
|
摘要
目的对比中重度癌痛合并抑郁患者单独采用羟考酮缓释片治疗或者联用氟伏沙明治疗的临床疗效。方法选取80例中重度癌痛合并抑郁患者为研究对象,分为参照组与实验组。给予参照组患者羟考酮缓释片口服治疗,实验组以羟考酮缓释片口服治疗为基础,给予患者氟伏沙明片口服治疗。将患者治疗前、治疗后的疼痛情况以及抑郁情况进行对比,并比较两组的不良反应发生率以及临床治疗总有效率。结果治疗前,实验组与参照组患者的疼痛VAS评分以及抑郁SDS评分均较高,组间差异无统计学意义(P> 0.05)。治疗后,两组的SDS评分和VAS评分均有所降低(P <0.05);且实验组的降低程度高于参照组(P <0.05)。实验组的不良反应发生率(7.50%)低于参照组(25.00%)(P <0.05)。实验组的临床治疗总有效率(95.00%)显著高于参照组(80.00%)(P <0.05)。结论在中重度癌痛合并抑郁患者的临床治疗中,采用羟考酮缓释片与氟伏沙明片联合治疗的效果明显优于单独采用羟考酮缓释片治疗的效果,联合用药可以明显缓解患者的抑郁和疼痛症状,提升临床治疗总有效率,且可降低羟考酮缓释片所引起的不良反应的发生率,值得临床推广。
Objective To compare the clinical curative effects of oxycodone sustained-release tablets alone or in combination with fluvoxamine in the treatment of patients with moderate to severe cancer pain combined with depression. Methods Eighty patients with moderate to severe cancer pain combined with depression were selected as research objects and they were divided into the reference group and experimental group.Patients in the reference group were given oral administration of oxycodone sustained-release tablets for treatment.On basis of oral administration of oxycodone sustained-release tablets,patients in the experimental group were given fluvoxamine tablets orally.The pain and depression of patients before and after treatment were compared,and the incidence of adverse reactions and the total effective rate of clinical treatment were compared between the two groups. Results Before treatment,the pain VAS score and depression SDS score of the experimental group and the reference group were higher,and the difference between the groups was not statistically significant(P > 0.05).After treatment,the SDS score and VAS score of the two groups were decreased(P < 0.05).And the degree of reduction in the experimental group was higher than that in the control group(P < 0.05).The incidence of adverse reactions in the experimental group(7.50%)was lower than that in the reference group(25.00%)(P < 0.05).The total effective rate of clinical treatment in the experimental group(95.00%)was significantly higher than that in the reference group(80.00%)(P < 0.05). Conclusion In the clinical treatment of patients with moderate to severe cancer pain combined with depression,the curative effect of oxycodone sustained-release tablets combined with fluvoxamine tablets is significantly better than oxycodone sustained-release tablets alone.The drug combination can alleviate the symptoms of depression and pain in patients,improve the total effective rate of clinical treatment and reduce the incidence of adverse reactions caused by oxycodone sustained-release tablets,which is worthy of clinical promotion.
Objective To compare the clinical curative effects of oxycodone sustained-release tablets alone or in combination with fluvoxamine in the treatment of patients with moderate to severe cancer pain combined with depression. Methods Eighty patients with moderate to severe cancer pain combined with depression were selected as research objects and they were divided into the reference group and experimental group.Patients in the reference group were given oral administration of oxycodone sustained-release tablets for treatment.On basis of oral administration of oxycodone sustained-release tablets,patients in the experimental group were given fluvoxamine tablets orally.The pain and depression of patients before and after treatment were compared,and the incidence of adverse reactions and the total effective rate of clinical treatment were compared between the two groups. Results Before treatment,the pain VAS score and depression SDS score of the experimental group and the reference group were higher,and the difference between the groups was not statistically significant(P > 0.05).After treatment,the SDS score and VAS score of the two groups were decreased(P < 0.05).And the degree of reduction in the experimental group was higher than that in the control group(P < 0.05).The incidence of adverse reactions in the experimental group(7.50%)was lower than that in the reference group(25.00%)(P < 0.05).The total effective rate of clinical treatment in the experimental group(95.00%)was significantly higher than that in the reference group(80.00%)(P < 0.05). Conclusion In the clinical treatment of patients with moderate to severe cancer pain combined with depression,the curative effect of oxycodone sustained-release tablets combined with fluvoxamine tablets is significantly better than oxycodone sustained-release tablets alone.The drug combination can alleviate the symptoms of depression and pain in patients,improve the total effective rate of clinical treatment and reduce the incidence of adverse reactions caused by oxycodone sustained-release tablets,which is worthy of clinical promotion.
引文
[1]赖如京,涂芸芸,邱火秀.羟考酮缓释片联合度洛西汀治疗晚期癌性疼痛的疗效及对患者外周血β-内啡肽水平的影响[J].黑龙江医药,2016,29(6):1148-1150.
[2]侯培锋,林小燕,陈强.盐酸羟考酮控释片治疗晚期癌症疼痛的临床疗效及安全性分析[J].中国医院药学杂志,2015,35(4):329-332.
[3]努尔比亚,孙靖,陈俊逾.疏肝解郁胶囊联合氟伏沙明治疗老年期抑郁症的疗效分析[J].内蒙古中医药,2017,36(14):41-42.
[4]卜岗,孙欣,王辉,等.盐酸羟考酮缓释片联合氟哌噻吨美利曲辛片治疗晚期癌痛的疗效观察[J].现代肿瘤医学,2018,26(4):609-612.
[5]李成彪,王玉珮,齐雪花,等.盐酸羟考酮缓释片治疗中重度癌痛的临床研究[J].湖南师范大学学报(医学版),2015,12(4):38-40.
[6]杨清,杨绍峰,张璐璐,等.氟伏沙明对癌症后抑郁患者血清褪黑素的影响[J].中国临床保健杂志,2017,20(6):676-678.
[7]朱伟,冯青.马来酸氟伏沙明对抑郁患者抑郁症状焦虑症状及生活质量的影响[J].山西医药杂志,2017,46(21):2641-2643.
[8]刘勇,宋正波,梁军,等.羟考酮缓释片和吗啡即释片在中重度癌痛滴定中疗效及安全性比较的Meta分析[J].临床肿瘤学杂志,2016,21(7):585-592.
[9]蔡明,楚敏,李晓宁.星状神经节阻滞联合盐酸羟考酮缓释片对癌痛患者免疫功能的影响[J].中国疼痛医学杂志,2015,21(2):146-148.
[10]刘君,肖扬,马益敏,等.氟伏沙明联合羟考酮缓释片治疗中重度癌痛[J].实用医学杂志,2015,31(12):2014-2017.
[11]童刚领,吴烜,靳枫,等.盐酸羟考酮缓释片联合即释吗啡片用于中重度癌痛患者滴定的疗效[J].现代肿瘤医学,2016,24(20):3267-3269.
[12]杨平,王昆.盐酸羟考酮缓释片用于癌痛治疗的滴定[J].中国肿瘤临床,2015,42(12):600-602,585.
[13]李改英,李薇,苏延军,等.盐酸羟考酮缓释片治疗晚期恶性肿瘤中重度疼痛的临床效果[J].中国医药导报,2017,38(14):92-95.
[14]朱荔丰.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗中重度癌痛的疗效观察[J].淮海医药,2015,33(1):89-90.
[15]吴海霞,陈燕平,沈齐,等.羟考酮缓释片联合吗啡片在癌痛滴定治疗中的应用[J].肿瘤药学,2015,5(2):112-115.
[16]彭秀兰,郭荣春,姚文秀,等.盐酸羟考酮缓释片治疗中重度癌痛的疗效及经济学分析[J].西部医学,2015,27(10):1538-1541.
[17]刘君,马益慧,马益敏,等.羟考酮缓释片单用或联合氟伏沙明治疗中重度癌痛合并抑郁的效果比较[J].中国医药,2016,11(9):1394-1397.
[2]侯培锋,林小燕,陈强.盐酸羟考酮控释片治疗晚期癌症疼痛的临床疗效及安全性分析[J].中国医院药学杂志,2015,35(4):329-332.
[3]努尔比亚,孙靖,陈俊逾.疏肝解郁胶囊联合氟伏沙明治疗老年期抑郁症的疗效分析[J].内蒙古中医药,2017,36(14):41-42.
[4]卜岗,孙欣,王辉,等.盐酸羟考酮缓释片联合氟哌噻吨美利曲辛片治疗晚期癌痛的疗效观察[J].现代肿瘤医学,2018,26(4):609-612.
[5]李成彪,王玉珮,齐雪花,等.盐酸羟考酮缓释片治疗中重度癌痛的临床研究[J].湖南师范大学学报(医学版),2015,12(4):38-40.
[6]杨清,杨绍峰,张璐璐,等.氟伏沙明对癌症后抑郁患者血清褪黑素的影响[J].中国临床保健杂志,2017,20(6):676-678.
[7]朱伟,冯青.马来酸氟伏沙明对抑郁患者抑郁症状焦虑症状及生活质量的影响[J].山西医药杂志,2017,46(21):2641-2643.
[8]刘勇,宋正波,梁军,等.羟考酮缓释片和吗啡即释片在中重度癌痛滴定中疗效及安全性比较的Meta分析[J].临床肿瘤学杂志,2016,21(7):585-592.
[9]蔡明,楚敏,李晓宁.星状神经节阻滞联合盐酸羟考酮缓释片对癌痛患者免疫功能的影响[J].中国疼痛医学杂志,2015,21(2):146-148.
[10]刘君,肖扬,马益敏,等.氟伏沙明联合羟考酮缓释片治疗中重度癌痛[J].实用医学杂志,2015,31(12):2014-2017.
[11]童刚领,吴烜,靳枫,等.盐酸羟考酮缓释片联合即释吗啡片用于中重度癌痛患者滴定的疗效[J].现代肿瘤医学,2016,24(20):3267-3269.
[12]杨平,王昆.盐酸羟考酮缓释片用于癌痛治疗的滴定[J].中国肿瘤临床,2015,42(12):600-602,585.
[13]李改英,李薇,苏延军,等.盐酸羟考酮缓释片治疗晚期恶性肿瘤中重度疼痛的临床效果[J].中国医药导报,2017,38(14):92-95.
[14]朱荔丰.盐酸羟考酮缓释片与硫酸吗啡缓释片治疗中重度癌痛的疗效观察[J].淮海医药,2015,33(1):89-90.
[15]吴海霞,陈燕平,沈齐,等.羟考酮缓释片联合吗啡片在癌痛滴定治疗中的应用[J].肿瘤药学,2015,5(2):112-115.
[16]彭秀兰,郭荣春,姚文秀,等.盐酸羟考酮缓释片治疗中重度癌痛的疗效及经济学分析[J].西部医学,2015,27(10):1538-1541.
[17]刘君,马益慧,马益敏,等.羟考酮缓释片单用或联合氟伏沙明治疗中重度癌痛合并抑郁的效果比较[J].中国医药,2016,11(9):1394-1397.